vs
亚什兰（ASH）与BIOCRYST PHARMACEUTICALS INC（BCRX）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是亚什兰的1.1倍（$406.6M vs $386.0M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs -3.1%，领先63.6%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs -4.7%），BIOCRYST PHARMACEUTICALS INC自由现金流更多（$291.2M vs $111.0M），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs -18.1%）
亚什兰是一家总部位于美国特拉华州威尔明顿的化工企业，1924年始创于肯塔基州亚什兰市，最初以炼油业务起家，1994年迁至现总部。公司拥有多个业务板块，覆盖化工中间体与溶剂、复合材料、工业特种化学品、个人及家居护理、制药、食品饮料以及农业相关领域，2017年之前曾是胜牌润滑油的主要生产商。
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
ASH vs BCRX — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $386.0M | $406.6M |
| 净利润 | $-12.0M | $245.8M |
| 毛利率 | 27.2% | 97.7% |
| 营业利润率 | -1.6% | 64.0% |
| 净利率 | -3.1% | 60.5% |
| 营收同比 | -4.7% | 209.1% |
| 净利润同比 | 92.7% | 1017.5% |
| 每股收益（稀释后） | $-0.26 | $1.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $386.0M | $406.6M | ||
| Q3 25 | $477.0M | $159.4M | ||
| Q2 25 | $463.0M | $163.4M | ||
| Q1 25 | $479.0M | $145.5M | ||
| Q4 24 | $405.0M | $131.5M | ||
| Q3 24 | $521.0M | $117.1M | ||
| Q2 24 | $544.0M | $109.3M | ||
| Q1 24 | $575.0M | $92.8M |
| Q4 25 | $-12.0M | $245.8M | ||
| Q3 25 | $31.0M | $12.9M | ||
| Q2 25 | $-742.0M | $5.1M | ||
| Q1 25 | $31.0M | $32.0K | ||
| Q4 24 | $-165.0M | $-26.8M | ||
| Q3 24 | $17.0M | $-14.0M | ||
| Q2 24 | $6.0M | $-12.7M | ||
| Q1 24 | $120.0M | $-35.4M |
| Q4 25 | 27.2% | 97.7% | ||
| Q3 25 | 33.3% | 98.6% | ||
| Q2 25 | 28.5% | 98.3% | ||
| Q1 25 | 30.7% | 96.9% | ||
| Q4 24 | 27.4% | 95.4% | ||
| Q3 24 | 33.2% | 97.3% | ||
| Q2 24 | 34.2% | 98.4% | ||
| Q1 24 | 28.0% | 98.6% |
| Q4 25 | -1.6% | 64.0% | ||
| Q3 25 | 12.8% | 18.6% | ||
| Q2 25 | -152.9% | 18.2% | ||
| Q1 25 | 10.6% | 14.6% | ||
| Q4 24 | -44.2% | -3.4% | ||
| Q3 24 | 6.1% | 6.6% | ||
| Q2 24 | -11.2% | 8.0% | ||
| Q1 24 | 3.7% | -15.6% |
| Q4 25 | -3.1% | 60.5% | ||
| Q3 25 | 6.5% | 8.1% | ||
| Q2 25 | -160.3% | 3.1% | ||
| Q1 25 | 6.5% | 0.0% | ||
| Q4 24 | -40.7% | -20.4% | ||
| Q3 24 | 3.3% | -12.0% | ||
| Q2 24 | 1.1% | -11.6% | ||
| Q1 24 | 20.9% | -38.1% |
| Q4 25 | $-0.26 | $1.13 | ||
| Q3 25 | $0.83 | $0.06 | ||
| Q2 25 | $-16.21 | $0.02 | ||
| Q1 25 | $0.65 | $0.00 | ||
| Q4 24 | $-3.50 | $-0.13 | ||
| Q3 24 | $0.34 | $-0.07 | ||
| Q2 24 | $0.12 | $-0.06 | ||
| Q1 24 | $2.39 | $-0.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $304.0M | $274.7M |
| 总债务越低越好 | $1.4B | — |
| 股东权益账面价值 | $1.9B | $-119.2M |
| 总资产 | $4.5B | $514.2M |
| 负债/权益比越低杠杆越低 | 0.74× | — |
8季度趋势，按日历期对齐
| Q4 25 | $304.0M | $274.7M | ||
| Q3 25 | $215.0M | $212.9M | ||
| Q2 25 | $207.0M | $260.0M | ||
| Q1 25 | $168.0M | $295.1M | ||
| Q4 24 | $219.0M | $320.9M | ||
| Q3 24 | $300.0M | $96.8M | ||
| Q2 24 | $399.0M | $78.4M | ||
| Q1 24 | $439.0M | $84.3M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.3B | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | — | ||
| Q2 24 | $1.3B | — | ||
| Q1 24 | $1.3B | — |
| Q4 25 | $1.9B | $-119.2M | ||
| Q3 25 | $1.9B | $-387.9M | ||
| Q2 25 | $1.9B | $-421.6M | ||
| Q1 25 | $2.6B | $-451.9M | ||
| Q4 24 | $2.6B | $-475.9M | ||
| Q3 24 | $2.9B | $-468.6M | ||
| Q2 24 | $3.0B | $-475.6M | ||
| Q1 24 | $3.1B | $-476.2M |
| Q4 25 | $4.5B | $514.2M | ||
| Q3 25 | $4.6B | $446.4M | ||
| Q2 25 | $4.6B | $457.2M | ||
| Q1 25 | $5.2B | $480.0M | ||
| Q4 24 | $5.2B | $490.4M | ||
| Q3 24 | $5.6B | $491.3M | ||
| Q2 24 | $5.7B | $472.4M | ||
| Q1 24 | $5.9B | $467.9M |
| Q4 25 | 0.74× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.52× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | 0.45× | — | ||
| Q1 24 | 0.42× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $125.0M | $292.0M |
| 自由现金流经营现金流 - 资本支出 | $111.0M | $291.2M |
| 自由现金流率自由现金流/营收 | 28.8% | 71.6% |
| 资本支出强度资本支出/营收 | 3.6% | 0.2% |
| 现金转化率经营现金流/净利润 | — | 1.19× |
| 过去12个月自由现金流最近4个季度 | $200.0M | $344.9M |
8季度趋势，按日历期对齐
| Q4 25 | $125.0M | $292.0M | ||
| Q3 25 | $40.0M | $41.6M | ||
| Q2 25 | $115.0M | $41.3M | ||
| Q1 25 | $9.0M | $-27.5M | ||
| Q4 24 | $-30.0M | $-5.2M | ||
| Q3 24 | $80.0M | $8.2M | ||
| Q2 24 | $127.0M | $-1.4M | ||
| Q1 24 | $54.0M | $-53.7M |
| Q4 25 | $111.0M | $291.2M | ||
| Q3 25 | $6.0M | $40.3M | ||
| Q2 25 | $95.0M | $41.1M | ||
| Q1 25 | $-12.0M | $-27.7M | ||
| Q4 24 | $-53.0M | $-5.9M | ||
| Q3 24 | $42.0M | $8.2M | ||
| Q2 24 | $98.0M | $-1.5M | ||
| Q1 24 | $20.0M | $-53.9M |
| Q4 25 | 28.8% | 71.6% | ||
| Q3 25 | 1.3% | 25.3% | ||
| Q2 25 | 20.5% | 25.2% | ||
| Q1 25 | -2.5% | -19.0% | ||
| Q4 24 | -13.1% | -4.5% | ||
| Q3 24 | 8.1% | 7.0% | ||
| Q2 24 | 18.0% | -1.4% | ||
| Q1 24 | 3.5% | -58.1% |
| Q4 25 | 3.6% | 0.2% | ||
| Q3 25 | 7.1% | 0.8% | ||
| Q2 25 | 4.3% | 0.1% | ||
| Q1 25 | 4.4% | 0.1% | ||
| Q4 24 | 5.7% | 0.5% | ||
| Q3 24 | 7.3% | 0.1% | ||
| Q2 24 | 5.3% | 0.1% | ||
| Q1 24 | 5.9% | 0.3% |
| Q4 25 | — | 1.19× | ||
| Q3 25 | 1.29× | 3.23× | ||
| Q2 25 | — | 8.12× | ||
| Q1 25 | 0.29× | -859.91× | ||
| Q4 24 | — | — | ||
| Q3 24 | 4.71× | — | ||
| Q2 24 | 21.17× | — | ||
| Q1 24 | 0.45× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASH
| Personal Care And Household | $123.0M | 32% |
| Other | $120.0M | 31% |
| Specialty Additives | $36.0M | 9% |
| Intermediates And Solvents | $31.0M | 8% |
| Personal Care | $30.0M | 8% |
| Life Sciences | $27.0M | 7% |
| Intermediates | $19.0M | 5% |
BCRX
暂无分部数据
